San Diego-based Design Therapeutics, which is developing therapies for patients with serious degenerative disorders caused by nucleotide repeat expansions, has raised $45M in a Series A financing round. The round was led by SR One, and also included Cormorant Asset Management, Quan Capital and WestRiver Group. The company said the funding will be used to to advance its lead therapeutic candidate into clinical development for the treatment of Friedreich’s ataxia, and support advancement of its discovery programs for multiple other degenerative diseases, including fragile X syndrome and myotonic dystrophy. Design Therapeutics’ founders are Pratik Shah, Ph.D., and Aseem Ansari, Ph.D.

Sourced from SoCal Tech